Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 1, 2013
Event Date: January 31, 2013
Context: The registrant amended and restated its By-laws to satisfy Nasdaq Stock Market listing requirements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a corporate governance report.
Material Changes
- By-laws Amendment: Article IX of the By-laws was revised to permit the issuance of both certificated and uncertificated shares of capital stock.
- Effective Date: Changes became effective immediately upon adoption by the Board of Directors on January 31, 2013.
- Purpose: The amendment is intended to satisfy specific requirements of the Nasdaq Stock Market in connection with the company's application to list its common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The sole focus is the administrative update to corporate by-laws.
Investor Verification Checklist
- Verify the status of the Nasdaq listing application referenced in the filing.
- Review the full text of the Amended and Restated By-laws (Exhibit 3.1) for any other governance changes.
- Confirm the company's current stock listing status on Nasdaq.